about
Treatment of advanced thyroid cancer with targeted therapies: ten years of experienceAssociation between BRAF V600E mutation and recurrence of papillary thyroid cancer.Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy.An idic(15) associated with POF (premature ovarian failure): molecular cytogenetic definition of a case and review of the literature.How to manage patients with differentiated thyroid cancer and a rising serum thyroglobulin level.Medullary thyroid carcinoma in children.The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?Targeted Therapy in Thyroid Cancer: State of the Art.Role of YAP-1 in Thyroid Tumor Progression and Outcome.Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer.Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation.In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life.KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease.BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience.Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer.Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study.Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience.New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations.RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC).Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience.Incidental versus clinically evident thyroid cancer: a 5-year follow-up studyLung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial TreatmentBRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid CancerModifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 YearsRisk of incident circulatory disease in patients treated for differentiated thyroid carcinoma with no history of cardiovascular diseaseSurgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomyThe BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort studyFifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent CasesManagement of Medullary Thyroid CancerBRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinomaLess than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body ScanPapillary thyroid microcarcinoma and active surveillance
P50
Q26747168-204514B2-55DA-4B8E-AA34-2F4DAB0FB2D4Q34716574-07638CA1-01FE-4042-9ECE-37F016953255Q36431628-0C9AA762-F604-4930-9F93-6E04DFC60F0AQ37216703-EBEAD3B2-CE82-487E-9A00-EC0C1F26E9F6Q37632231-3938CA9D-E0E4-4D4E-B903-C3B948A1082CQ38009159-83DB2559-551E-4971-A452-9BDF404663C5Q38217158-0E614055-5402-45BB-B4B2-BD41ADBA86FBQ38251062-BA1DE340-9336-48D7-8737-88099A944848Q38743211-AD81C6BF-BAA9-43DE-873A-F4451E27BCB7Q39091785-9BCC62CA-EE7E-47AD-8FFC-B72B5421E58FQ39187719-2FBFC8C8-BB5F-4AA0-960E-3525F071E739Q39278171-5CC99D48-731E-4596-9798-66CF6FE3F096Q39374983-979B695B-229D-4DE9-874C-FB2A483A8EAEQ40435796-26B9FF78-00EF-41D4-AF95-9B3D1052C601Q42807276-6E616781-4AC2-4EC4-9DA4-E8CE4846E32DQ47800528-E49FA648-F41A-42DF-9D8B-A323E9B627CAQ47801382-86A0D74B-770E-4F2C-A24C-09DC36F187C0Q49808093-DC10C968-D228-4AAF-A4C6-029C39B4C069Q50129636-424E4141-2CB4-4B6C-83D7-97AE3A09F4D0Q50146629-A529DC48-3B19-424A-BDC6-432F4B9206BAQ51017646-EE58ED00-6B24-4352-9958-D55BD911DA52Q51545085-8CD1AF9B-7529-4E08-8BB6-9D4EAE7CDBA5Q52984965-8A7781F0-7C6C-4492-A87E-7472F12CC3E6Q53164620-D239EF62-603B-4F52-9460-5453BAEE2BEBQ55332960-79DD6476-AAC6-407E-9AF3-6F57A84CD3C0Q57643470-FF692960-3203-4E3D-9D7C-15C50227C896Q57816627-B9CC055D-4DC1-4E22-B394-31391AC70287Q58802686-BC737CC9-46C5-4630-BB8C-6F892E75AD16Q62505666-D1ACD66F-8CB2-49AE-928E-05FEAF115FDEQ64110943-98BA3F1B-7F67-4649-B648-9B349B3DC6DFQ83366368-D7E752F1-11F8-4D92-A2C0-BBC1BC88D3A5Q87444391-3877D41E-BF25-452B-B0C9-40D62769627DQ90824879-77296BAF-E9B9-4AFD-AD7A-017AF6EF7AE4Q91338304-CCBFA5D7-20D8-4B39-B2DE-A40308EFC633Q91608758-BC0F9D15-3D45-4B33-B12E-9A2D2E5FFB4DQ92704011-FF4A4FEC-AC69-48DF-A68A-6F9001063A99Q95364155-4D11A2F7-143A-46AE-B156-486AFE1365CC
P50
description
investigador
@es
onderzoeker
@nl
researcher
@en
name
david viola
@ast
david viola
@en
david viola
@es
david viola
@nl
type
label
david viola
@ast
david viola
@en
david viola
@es
david viola
@nl
altLabel
David Viola
@en
prefLabel
david viola
@ast
david viola
@en
david viola
@es
david viola
@nl
P106
P1153
25228034500
P31
P496
0000-0001-7683-152X